Literature DB >> 21903324

Targeting p73 in cancer.

Anna-Maria Maas1, Anne Catherine Bretz, Elisabeth Mack, Thorsten Stiewe.   

Abstract

p73 is a member of the p53 family of tumor suppressors. Transactivating isoforms of p73 (TAp73) have p53-like, anti-proliferative and pro-apoptotic activities that are crucial for an efficient chemotherapy response. In line with this, genetic studies in mice have confirmed that TAp73 acts as a tumor suppressor. However, in contrast to p53, which is commonly inactivated in human cancer by point mutations, the TP73 gene is almost never mutated. Instead, the tumor suppressor activity of TAp73 is inhibited through a variety of mechanisms including epigenetic silencing and complex formation with inhibitory proteins. All these mechanisms have in common that they are in principle reversible and therefore amenable to therapeutic intervention. Here, we will review how tumor cells control the tumor suppressor activity of TAp73 and discuss possible strategies targeting p73 for reactivation.
Copyright © 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21903324     DOI: 10.1016/j.canlet.2011.07.030

Source DB:  PubMed          Journal:  Cancer Lett        ISSN: 0304-3835            Impact factor:   8.679


  17 in total

1.  Analysis of the oligomeric state and transactivation potential of TAp73α.

Authors:  L M Luh; S Kehrloesser; G B Deutsch; J Gebel; D Coutandin; B Schäfer; M Agostini; G Melino; V Dötsch
Journal:  Cell Death Differ       Date:  2013-03-29       Impact factor: 15.828

Review 2.  p53/p63/p73 in the epidermis in health and disease.

Authors:  Vladimir A Botchkarev; Elsa R Flores
Journal:  Cold Spring Harb Perspect Med       Date:  2014-08-01       Impact factor: 6.915

Review 3.  The significance of genetics for cholangiocarcinoma development.

Authors:  Luca Maroni; Irene Pierantonelli; Jesus M Banales; Antonio Benedetti; Marco Marzioni
Journal:  Ann Transl Med       Date:  2013-10

4.  Effect of combined 5-aza-2'deoxycytidine and cisplatin treatment on the P15 lung adenocarcinoma cell line.

Authors:  Kaishan Liu; Wenyan Huang; Weisong Gao; Wenfang He
Journal:  Oncol Lett       Date:  2015-02-26       Impact factor: 2.967

5.  Use of signals of positive and negative selection to distinguish cancer genes and passenger genes.

Authors:  László Bányai; Maria Trexler; Krisztina Kerekes; Orsolya Csuka; László Patthy
Journal:  Elife       Date:  2021-01-11       Impact factor: 8.140

6.  JNK-NQO1 axis drives TAp73-mediated tumor suppression upon oxidative and proteasomal stress.

Authors:  A Kostecka; A Sznarkowska; K Meller; P Acedo; Y Shi; H A Mohammad Sakil; A Kawiak; M Lion; A Królicka; M Wilhelm; A Inga; J Zawacka-Pankau
Journal:  Cell Death Dis       Date:  2014-10-23       Impact factor: 8.469

7.  Decitabine and Melphalan Fail to Reactivate p73 in p53 Deficient Myeloma Cells.

Authors:  Pierre-Samuel Gillardin; Géraldine Descamps; Sophie Maiga; Benoit Tessoulin; Hanane Djamai; Benedetta Lucani; David Chiron; Philippe Moreau; Steven Le Gouill; Martine Amiot; Catherine Pellat-Deceunynck; Agnès Moreau-Aubry
Journal:  Int J Mol Sci       Date:  2017-12-23       Impact factor: 5.923

8.  Pirh2, an E3 ligase, regulates the AIP4-p73 regulatory pathway by modulating AIP4 expression and ubiquitination.

Authors:  Rami Abou Zeinab; H Helena Wu; Yasser Abuetabh; Sarah Leng; Consolato Sergi; David D Eisenstat; Roger P Leng
Journal:  Carcinogenesis       Date:  2021-04-30       Impact factor: 4.944

9.  Eradication of metastatic melanoma through cooperative expression of RNA-based HDAC1 inhibitor and p73 by oncolytic adenovirus.

Authors:  Holger Schipper; Vijay Alla; Claudia Meier; Dirk M Nettelbeck; Ottmar Herchenröder; Brigitte M Pützer
Journal:  Oncotarget       Date:  2014-08-15

10.  P53-derived hybrid peptides induce apoptosis of synovial fibroblasts in the rheumatoid joint.

Authors:  Shih-Yao Chen; Ai-Li Shiau; Chao-Liang Wu; Chrong-Reen Wang
Journal:  Oncotarget       Date:  2017-12-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.